文献速递糖尿病

毛里求斯1987至2021年基于口服葡萄糖耐量试验的2型糖尿病和中间高血糖患病率趋势

Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-09-30

该研究基于毛里求斯1987至2021年七次全国非传染性疾病风险因素调查,采用口服葡萄糖耐量试验(OGTT)和WHO 2006标准诊断。

要点

  • 毛里求斯是首个用OGTT金标准显示2型糖尿病和中间高血糖患病率随时间下降的国家。

核心结论

  • 毛里求斯2型糖尿病和中间高血糖年龄及性别标化患病率在2009年达峰后显著下降。
  • 全国性预防控制努力可降低2型糖尿病负担,OGTT系统监测至关重要。

研究设计与样本

  • 重复横断面研究,1987、1992、1998、2004、2009、2015和2021年七次调查。
  • 共36 744人次25-74岁成人参与,每次调查参与率超过85%。
  • 采用标准化方案,测量空腹血糖并对符合条件者行OGTT,按WHO 2006标准分类血糖状态。

主要发现

  • 2型糖尿病患病率下降在性别、年龄组和种族间方向一致。

关键数值与推荐

  • 血糖状态按WHO 2006标准分类。

临床怎么用

  • OGTT可作为人群糖尿病和中间高血糖监测的客观金标准工具。
  • 应系统监测糖尿病及中间高血糖发生率以评估防控效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on national trends in the prevalence of type 2 diabetes and intermediate hyperglycaemia using the oral glucose tolerance test (OGTT) are scarce. We aimed to identify trends in the prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius, a country that has monitored prevalence over 34 years using OGTT. METHODS: Non-communicable disease risk factor surveys using standardised protocols were conducted in the general population in 1987, 1992, 1998, 2004, 2009, 2015, and 2021 in Mauritius, with 36 744 survey attendances by adults aged 25-74 years examined. The participation rate was more than 85% in each survey. Participants had fasting plasma glucose measured at the survey site by site staff, and those who were not pregnant or taking glucose-lowering medication had an OGTT. Blood samples were immediately centrifuged to isolate plasma for glucose measurement. Glycaemic status was classified according to WHO 2006 criteria. FINDINGS: In 1987, the age and sex-standardised prevalence of type 2 diabetes in Mauritius was 14·7% (698 of 5017 people; 95% CI 13·7-15·7), which increased gradually, peaking at 23·3% (1599 of 5833; 22·4-24·3) in 2009, and decreased significantly to 19·9% (899 of 3343; 18·6-21·1) in 2021. This decrease was consistent in direction across sexes, age groups, and ethnicities. The age and sex-standardised prevalence of intermediate hyperglycaemia was 20·8% (1024 of 5017 people; 95% CI 19·6-21·9) in 1987, peaked at 24·9% (1495 of 5833; 23·8-26·1) in 2009, and declined to 15·6% (580 of 3343; 14·3-16·9) in 2021. The proportion of all individuals with type 2 diabetes who were newly diagnosed decreased from 67·0% in 1987 (468 of 698 people) to 32·5% (292 of 899) in 2021. INTERPRETATION: Mauritius is the first country to show a decreasing prevalence of type 2 diabetes and intermediate hyperglycaemia over time, using the objective, gold standard OGTT-based diagnostic criteria recommended by the WHO. These results underscore that national efforts to prevent and control type 2 diabetes can reduce its burden; systematic monitoring of diabetes and intermediate hyperglycaemia occurrence using the OGTT is crucial. FUNDING: Mauritian Ministry of Health and Wellness.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Tuomilehto J, Kowlessur S, Zimmet P, et al. Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study. Lancet Diabetes Endocrinol. 2026. PMID: 42815503. doi:10.1016/S2213-8587(26)00127-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。